Skip to content

Venture

LOGO 1-01

Affiliations

New York University

Technologies

Therapeutic

Indication

Basic Research

Clinical Research

Dermatology

Drug Discovery

Fibrosis

Personalized Medicine

Regenerative Medicine

Additional Information

Women Founded

CalRegen, Inc is a start-up biotechnology company formed on the discovery of calreticulin (CRT), as a novel biotherapeutic that has unique, diverse and broad ranging tissue regenerative qualities that will be developed for different indications including chronic wound healing, epidermal appendage (hair follicle) neogenesis, improving the cosmetic architecture of the skin, and healing of ophthalmic ulcers.

 

CalRegen, Inc. Team:

Executive Leadership:

Leslie I Gold, PhD, Founder, CSO

Glenn Cornett, MD, PhD, CEO

Board:

Aron Wahrman, MD, MBA,MHCDS, FACS

Mark P Solomon, MD

Marek Michalak, PhD, Founder

Eric Hermann, Chair, Founder

Dennis Hranitzky, JD, Dechert, LLP Scientific Advisory Board

Elma Hawkins, PhD, Advisor